Abstract
A key hurdle for the further development of RNA interference (RNAi) therapeutics like small interfering RNA (siRNA) is their safe and effective delivery. Lipids are promising and versatile carriers because they are based on Natures own building blocks and can be provided with properties which allow for protection of the siRNA, steric stabilization, targeting, membrane fusion and triggered drug release. At present a variety of lipid-based transfectants for siRNA delivery have been used for in vitro and in vivo purposes. The majority bears a cationic charge to electrostatically complex the siRNA into more hydrophobic lipoplexes, which promote passage of the siRNA across cellular membrane barriers, especially when lipids are added that facilitate membrane fusion. Despite these attractive features, siRNA delivery vehicles are facing a number of challenges such as the limited delivery efficiency in vivo, toxicity and non-specific stimulation of the immune system. To optimally design and tailor the lipidic systems for siRNA delivery, better insight is needed into the mechanisms of cell delivery. More specifically, further clarification is need regarding the nature of cell surface interactions, routes of internalization, passage of intracellular membranes, and mechanisms of immune activation. This review provides an overview of the main constituents currently employed in lipid-based siRNA carriers, and recent research into improvements of cell delivery. In addition, pitfalls related to immune activation and side effects are discussed, and possible ways to overcome them are highlighted.
Keywords: siRNA, RNAi, delivery, lipid, liposomes, immune activation, intracellular membranes, steric stabilization, hydrophobic lipoplexes, mechanisms of immune activation, siRNA delivery vehicles, fundamental gene silencing mechanism, cell cytoplasm, physicochemical characteristics of the molecule, Several clinical trials
Current Topics in Medicinal Chemistry
Title: siRNA Delivery with Lipid-based Systems: Promises and Pitfalls
Volume: 12 Issue: 2
Author(s): Camilla Foged
Affiliation:
Keywords: siRNA, RNAi, delivery, lipid, liposomes, immune activation, intracellular membranes, steric stabilization, hydrophobic lipoplexes, mechanisms of immune activation, siRNA delivery vehicles, fundamental gene silencing mechanism, cell cytoplasm, physicochemical characteristics of the molecule, Several clinical trials
Abstract: A key hurdle for the further development of RNA interference (RNAi) therapeutics like small interfering RNA (siRNA) is their safe and effective delivery. Lipids are promising and versatile carriers because they are based on Natures own building blocks and can be provided with properties which allow for protection of the siRNA, steric stabilization, targeting, membrane fusion and triggered drug release. At present a variety of lipid-based transfectants for siRNA delivery have been used for in vitro and in vivo purposes. The majority bears a cationic charge to electrostatically complex the siRNA into more hydrophobic lipoplexes, which promote passage of the siRNA across cellular membrane barriers, especially when lipids are added that facilitate membrane fusion. Despite these attractive features, siRNA delivery vehicles are facing a number of challenges such as the limited delivery efficiency in vivo, toxicity and non-specific stimulation of the immune system. To optimally design and tailor the lipidic systems for siRNA delivery, better insight is needed into the mechanisms of cell delivery. More specifically, further clarification is need regarding the nature of cell surface interactions, routes of internalization, passage of intracellular membranes, and mechanisms of immune activation. This review provides an overview of the main constituents currently employed in lipid-based siRNA carriers, and recent research into improvements of cell delivery. In addition, pitfalls related to immune activation and side effects are discussed, and possible ways to overcome them are highlighted.
Export Options
About this article
Cite this article as:
Foged Camilla, siRNA Delivery with Lipid-based Systems: Promises and Pitfalls, Current Topics in Medicinal Chemistry 2012; 12 (2) . https://dx.doi.org/10.2174/156802612798919141
DOI https://dx.doi.org/10.2174/156802612798919141 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Current Medicinal Chemistry Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets Progress in the Development of Matrix Metalloproteinase Inhibitors
Current Medicinal Chemistry MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis
Current Drug Targets Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued) HGF/MET Signaling in Ovarian Cancer
Current Molecular Medicine Predicting Drug Efficacy Using Integrative Models for Chronic Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Heparan Sulfate Proteoglycans in Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effect of Bitter Melon (Momordica charantia) Extract on the Uptake of <sup>99m</sup>Tc Labeled Paclitaxel: In Vitro Monitoring in Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Rate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy
Current Gene Therapy Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders SALL4: Engine of Cell Stemness
Current Gene Therapy Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Cigarette Smoke-Induced Proteostasis Imbalance in Obstructive Lung Diseases
Current Molecular Medicine Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Current Medicinal Chemistry